1600529-79-0

Basic information

• Product Name: N-(2-formylphenyl)-2-naphthamide
• Synonyms: N-(2-formylphenyl)-2-naphthamide
• CAS NO: 1600529-79-0
• Molecular Weight: 275.307
• Mol File: 1600529-79-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(2-formylphenyl)-2-naphthamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-formylphenyl)-2-naphthamide(1600529-79-0)
• EPA Substance Registry System: N-(2-formylphenyl)-2-naphthamide(1600529-79-0)

Safety Data

• Hazardous Substances Data: 1600529-79-0(Hazardous Substances Data)

Upstream product

• 10335-79-2 naphthalene-2-carboxylic acid hydroxyamide 
• 100-52-7 benzaldehyde 
• 927639-32-5 N-(2-(hydroxymethyl)phenyl)-2-naphthamide 
• 5344-90-1 2-Aminobenzyl alcohol 
• 2243-83-6 2-naphthaloyl chloride 
• 5339-85-5 2-aminophenethyl alcohol 
• 529-23-7 o-aminobenzaldehyde 

Downstream Products

• 1600529-91-6 4-((2-(2-naphthamido)benzyl)amino)butanoic acid 

Relevant articles and documents

Experimental and computational studies on H2O-promoted, Rh-catalyzed transient-ligand-free ortho-C(sp2)-H amidation of benzaldehydes with dioxazolones

An efficient and convenient ligand-free, rhodium-catalyzed ortho-C(sp2)-H amidation of benzaldehydes with dioxazolones using H2O as the key promoter is described. Using this protocol, a wide range of benzaldehyde substrates were selectively amidated in good to excellent yields with broad functional group compatibility. KIE experiments revealed that the C-H bond activation was likely the rate-limiting step. In addition, computational studies indicated that the catalyst precursor interacted with water and dioxazolones to generate the active catalytic species. Notably, the practicality and efficacy of this method were illustrated by a late-stage amidation of an estrone-derived molecule and further transformations of the amidated product.

Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR)

Nuclear farnesoid X receptor (FXR) has important physiological roles in various metabolic pathways including bile acid, cholesterol and glucose homeostasis. The clinical use of known synthetic non-steroidal FXR ligands is restricted due to toxicity or poor bioavailability. Here we report the development, synthesis, in vitro activity and structure-activity relationship (SAR) of anthranilic acid derivatives as novel FXR ligands. Starting from a virtual screening hit we optimized the scaffold to a series of potent partial FXR agonists with appealing drug-like properties. The most potent derivative exhibited an EC50 value of 1.5 ± 0.2 μM and 37 ± 2% maximum relative FXR activation. We investigated its SAR regarding polar interactions with the receptor by generating derivatives and computational docking.